Details of the Drug Combination

General Information of Drug Combination (ID: DCGWCSC)

Drug Combination Name
Rifaximin Acetylcysteine
Indication
Disease Entry Status REF
Irritable Bowel Syndrome With Diarrhea Phase 1 [1]
Component Drugs Rifaximin   DMW1TV2 Acetylcysteine   DMWSXI4
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Rifaximin
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [2]
Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [3]
Hepatic encephalopathy DB99.5 Approved [3]
Rifaximin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Rifaximin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Rifaximin Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [8]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [8]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Expression [9]
------------------------------------------------------------------------------------
Indication(s) of Acetylcysteine
Disease Entry ICD 11 Status REF
Amyloidosis 5D00 Approved [4]
Bronchiectasis CA24 Approved [4]
Bronchitis CA20 Approved [4]
Bulimia nervosa 6B81 Approved [4]
Ischemia-reperfusion injury DB98.B Approved [4]
Liver disease DB90-BD99 Approved [5]
Paracetamol poisoning N.A. Approved [4]

References

1 ClinicalTrials.gov (NCT04557215) Efficacy and Safety of Rifaximin With NAC in IBS-D
2 ClinicalTrials.gov (NCT01654939) Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease. U.S. National Institutes of Health.
3 Rifaximin FDA Label
4 Acetylcysteine FDA Label
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability. AAPS J. 2017 May;19(3):806-813.
7 Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth. Ann Pharmacother. 2011 May;45(5):e25.
8 Solomonsterols A and B from Theonella swinhoeiThe first example of C-24 and C-23 sulfated sterols from a marine source endowed with a PXR agonistic activity. J Med Chem. 2011 Jan 13;54(1):401-5.
9 Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity. J Med Chem. 2011 Jul 14;54(13):4590-9. doi: 10.1021/jm200241s. Epub 2011 Jun 3.